BT involves the controlled application of heat in the lungs to improve pulmonary function and reduce asthma symptoms. This therapy is used to ward off asthma attacks.
In a recent international study with patients with severe asthma, 50% of the study subjects were able to completely stop taking their inhaled steroids after undergoing BT. One year later, they were still having positive asthma control. Commercial acceptance, however, is still a few years away.
Where Are They Now
New anticoagulant treatments are being introduced with the goal of curbing complications such as bleeding and thrombosis. Compared to existing therapies, these agents continue to hold great promise for providing effective anticoagulation for patients with atrial fibrillation or who are at risk for deep venous thrombosis. Early results of clinical trials with these new agents suggest that they may be used with decreased complications and easier monitoring compared with existing treatments.
The FDA approved dabigatran in 2010, and there are now two Factor X drugs commercially available.